Extracellular vesicles encapsulated with caspase-1 inhibitor ameliorate experimental autoimmune myasthenia gravis...

Area of Science:

• Immunology
• Neuroimmunology
• Drug Delivery Systems

Background:

• Caspase-1 (cysteinyl aspartate-specific proteinase-1) is a key inflammatory mediator implicated in various diseases.
• Caspase-1 inhibitors show therapeutic potential in myasthenia gravis models but face limitations due to tissue toxicity and off-target effects.

Purpose of the Study:

• To investigate the therapeutic efficacy and mechanism of dendritic cell-derived extracellular vesicles (EVs) loaded with a caspase-1 inhibitor (VX-765) for treating myasthenia gravis.
• To evaluate the safety and effectiveness of EV-mediated drug delivery compared to conventional administration.

Main Methods:

• Dendritic cell-derived EVs were loaded with the caspase-1 inhibitor VX-765 (EVs-VX-765).
• The uptake of EVs-VX-765 by immune cells, primarily macrophages, was assessed.
• Therapeutic effects were evaluated in a myasthenia gravis model, focusing on macrophage-dependent mechanisms, interleukin-1β levels, Th17 responses, and germinal center reactions.

Main Results:

• EVs-VX-765 were preferentially phagocytized by macrophages, where caspase-1 is expressed.
• EVs-VX-765 demonstrated significant therapeutic benefits by inhibiting interleukin-1β, Th17 responses, and germinal center reactions.
• EVs-VX-765 exhibited superior therapeutic effects compared to conventional VX-765 doses, despite lower drug loading, and reduced tissue toxicity.

Conclusions:

• EV-mediated delivery of caspase-1 inhibitors represents a targeted and effective strategy for managing myasthenia gravis.
• This approach offers a promising alternative to conventional therapies, mitigating toxicity and enhancing therapeutic outcomes.
• The findings support the potential clinical application of extracellular vesicle-based drug delivery systems for autoimmune diseases.